PlA1/PlA2 polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty

Blood Coagulation and Fibrinolysis

Volumn 24, Issue 4, 2013, Pages 411-418

  Verdoia, Monica ^a   Pergolini, Patrizia ^a   Camaro, Cyril ^b   Restifo, Maria ^a   Rolla, Roberta ^a   Schaffer, Alon ^a   Di Giovine, Gabriella ^a   Marino, Paolo ^a   Bellomo, Giorgio ^a   Suryapranata, Harry ^b   De Luca, Giuseppe ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Gp IIb IIIa inhibitors; platelet glycoprotein IIIa; platelet polymorphism

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART MUSCLE REVASCULARIZATION; HUMAN; IMPEDANCE; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT RESPONSE; WILD TYPE;

AGED; AMINO ACID SUBSTITUTION; ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LEUCINE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POLYMORPHISM, GENETIC; PROLINE; TREATMENT OUTCOME; TYROSINE;

EID: 84877692380     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32835d546e     Document Type: Article

References (36)

1. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Guidelines on myocardial revascularization. Eur Heart J 2010;31:2501-2555.
2. Siller-Matula J, Schrör K, Wojta J, Huber K. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007;97:385-393. (Pubitemid 46437800)
3. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005;293:1759-1765.
4. De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J 2009;30:2705-2713.
5. De Luca G, Gibson CM, Bellandi F, Murphy S, Maioli M, Noc M, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis. Heart 2008;94:1548-1558.
6. De Luca G, Bellandi F, Huber K, Noc M, Petronio AS, Arntz HR, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis. J Thromb Haemost 2011;9:2361-2370.
7. De Luca G. Glycoprotein IIb-IIIa Inhibitors. Cardiovasc Ther 2011;30:e242-e254.
8. De Luca G, Cassetti E, Marino P. Percutaneous coronary interventionrelated time delay, patient's risk profile, and survival benefits of primary angioplasty vs lytic therapy in ST-segment elevation myocardial infarction. Am J Emerg Med 2009;27:712-719.
9. De Luca G, Biondi-Zoccai G, Marino P. transferring patients with STsegment elevation myocardial infarction for mechanical reperfusion: a meta-regression analysis of randomized trials. Ann Emerg Med 2008;52:665-676.
10. De Luca G, van 't Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, et al. Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Am Heart J 2005;150:557-562. (Pubitemid 41317629)
11. De Luca G, van 't Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, et al. Ageing, impaired myocardial perfusion, and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Eur Heart J 2005;26:662-666. (Pubitemid 40516877)
12. De Luca G, Smit JJ, Ernst N, Suryapranata H, Ottervanger JP, Hoorntje JC, et al. Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Thromb Haemost 2005;93:820-823. (Pubitemid 40691536)
13. De Luca G, Ucci G, Cassetti E, Marino P. Benefits from small molecule administration as compared with abciximab among patients with STsegment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. J Am Coll Cardiol 2009;53:1668-1673.
14. Wheeler GL, Braden GA, Bray PF, Marciniak SJ, Mascelli MA, Sane DC. Reduced inhibition by abciximab in platelets with the PlA2 polymorphism. Am Heart J 2002;143:76-82. (Pubitemid 34056378)
15. Coller BS. A new murine monoclonal antibody reports an activationdependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985;76:101-108. (Pubitemid 15240423)
16. Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989;83:1778-1781. (Pubitemid 19124140)
17. Ong FS, Deignan JL, Kuo JZ, Bernstein KE, Rotter JI, Grody WW, Das K. Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. Pharmacogenomics 2012;13:465-475.
18. Narins CR, Topol EJ. Attention shifts to the white clot. Lancet 1997;350 (Suppl 3):2.
19. Handin RI. Platelets and coronary artery disease. N Engl J Med 1996;334:1126-1127.
20. Ernst NM, Suryapranata H, Miedema K, Slingerland RJ, Ottervanger JP, Hoorntje JC, et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST segment elevation myocardial infarction. J Am Coll Cardiol 2004;44:1187-1193. (Pubitemid 39208872)
21. Kabbani SS, Aggarwal A, Terrien EF, DiBattiste PM, Sobel BE, Schneider DJ. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol 2002;89:647-650. (Pubitemid 34178590)
22. Feng D, Lindpaintner K, Larson MG, Rao VS, O'Donnell CJ, Lipinska I, et al. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 1999;19:1142-1147. (Pubitemid 29177367)
23. Loncar R, Stoldt V, Hellmig S, Zotz RB, Mihalj M, Scharf RE. HPA-1 polymorphism of alphaIIbbeta3 modulates platelet adhesion onto immobilized fibrinogen in an in-vitro flow system. Thromb J 2007;5:2.
24. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996;334:1090-1094. (Pubitemid 26120186)
25. Zotz RB, Klein M, Dauben HP, Moser C, Gams E, Scharf RE. Prospective analysis after coronary-artery bypass grafting: platelet GP IIIa polymorphism (HPA-1b/PIA2) is a risk factor for bypass occlusion, myocardial infarction, and death. Thromb Haemost 2000;83:404-407. (Pubitemid 30148352)
26. Walter DH, Schächinger V, Elsner M, Dimmeler S, Zeiher AM. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet 1997;350:1217-1219. (Pubitemid 127445095)
27. Kastrati A, Schomig A, Seyfarth M, Koch W, Elezi S, Böttiger C, et al. PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation 1999;99:1005-1010. (Pubitemid 29104488)
28. Böttiger C, Kastrati A, Koch W, Mehilli J, Seidl H, Schömig K, et al. HPA-1 and HPA-3 polymorphisms of the platelet fibrinogen receptor and coronary artery disease and myocardial infarction. Thromb Haemost 2000;83:559-562. (Pubitemid 30201131)
29. Park S, Park HY, Park C, Ko YG, Im EK, Jo I, et al. Association of the gene polymorphisms of platelet Glycoprotein Ia e IIb/IIIa with myocardial infarction and extent of coronary artery disease in the Korean population. Yonsei Med J 2004;45:428-434 (Pubitemid 39010700)
30. Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rüdiger S, Taubitz W, et al. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors. Thromb Haemost 2000;83:915-922. (Pubitemid 30411694)
31. Schrör K, Weber AA. Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis 2003;15:71-80. (Pubitemid 37498175)
32. Wencel-Drake JD, Boudognon-Proudhon-Boudignon C, Dieter MG, Criss AB, Parise LV. Internalization of bound fibrinogen modulates platelet aggregation. Blood 1996;87:602-612. (Pubitemid 26030315)
33. Weber AA, Jacobs C, Meila D, Weber S, Zotz RB, Scharf RE, et al. No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein IIb/IIIa inhibitors. Pharmacogenetics 2002;12:581-583. (Pubitemid 35177089)
34. Mahmud E, Cavendish JJ, Tsimikas S, Ang L, Nguyen C, Bromberg-Marin G, et al. Elevated plasma fibrinogen level predicts suboptimal response to therapy with both single-and double-bolus eptifibatide during percutaneous coronary intervention. J Am Coll Cardiol 2007;49:2163-2171. (Pubitemid 46817810)
35. Renda G, Rocca B, Crocchiolo R, Cristofaro RD, Landolfi R. Effect of fibrinogen concentration and platelet count on the inhibitory effect of abciximab and tirofiban. Thromb Haemost 2003;89:348-354. (Pubitemid 36227287)
36. Paniccia R, Antonucci E, Maggini N, Romano E, Gori AM, Marcucci R, et al. Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am J Clin Pathol 2009;131:834-842.